Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.
News|Articles|January 1, 2003
A comparison of the newer treatment options for ADHD (PDF)
Psychostimulant drugs have consistently demonstrated efficacy in the treatment of attention-deficit/hyperactivity disorder (ADHD). Innovative technology has fueled the development of novel release mechanisms and isolation of active enantiomer components with the hopes of enhancing the duration of action and improving the safety and effectiveness. As a result, several new stimulant agents have recently been added to the arsenal of ADHD treatment options. Formulary selection is complicated by the high costs and small but distinct differences among these agents. The five newest FDA-approved stimulant agents for the treatment of ADHD are detailed, and a brief summary of future treatment options, including a recently approved nonstimulant agent, is provided.
Advertisement
Advertisement
Related to this article
Christopher Stanley, M.D., MBA, says Henry Ford Health's growth has led Populance to put its push for outside customers on hold and focus on its own system.
Geisinger Health Plan President Jeremy Gaskill says being owned by a health system aligns incentives, cuts payer-provider busywork and speeds care to patients.
Geisinger Health Plan expects Medicaid enrollment to fall roughly 10% as H.R. 1 takes effect, President Jeremy Gaskill says, though the timing is still unclear.
As other insurers pull back, Geisinger Health Plan isn’t exiting any Medicare Advantage plans for 2027 and expects to grow, President Jeremy Gaskill says.
The second part of our interview with Jeremy Gaskill, the president of the Geisinger Health Plan. Gaskill discusses trends in the various segments of the health insurance market—Medicaid, Medicare Advantage, the employer-based commercial market and the ACA marketplace.
Democrats won Congress, but with Trump’s veto, their best healthcare tools are funding bills, hearings and bipartisan deals.
In the CONNECT trial, CGM users with type 2 diabetes not on insulin saw larger A1C reductions and more time in range than those using finger-stick testing.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
On Medicaid cuts, the Medicare Advantage market, commercial insurance and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
2
CVS Health is splitting in two, according to news reports
3
The CVS Health split. How separate will the two companies really be?
4
On the advantages of health system-owned health plan, what Medicaid cuts might mean and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
5